Drug profile · INN
ceftobiprole medocaril sodium
ZEVTERA
ceftobiprole medocaril sodium (ZEVTERA) is a meca inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — ceftobiprole medocaril sodium
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ceftobiprole medocaril sodium (ZEVTERA) is a meca inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
MecA inhibitor
Primary target: MecA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is ceftobiprole medocaril sodium?
ceftobiprole medocaril sodium (ZEVTERA) is a meca inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for ceftobiprole medocaril sodium?
ZEVTERA is a marketed brand name for ceftobiprole medocaril sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ceftobiprole medocaril sodium?
ceftobiprole medocaril sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.